Generic Name: dupilumab
Brand Name: Dupixent
Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
Indications: atopic dermatitis
Manufacturer Requested Reimbursement Criteria1: For the treatment of patients aged 12 years and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and/or who are refractory to or ineligible for systemic immunosuppressant therapies (i.e., due to contraindications, intolerance, or need for long-term treatment).
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule B
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||September 23, 2019|
|Patient group input closed||November 12, 2019|
- Patient input submission received from Eczema Society of Canada
|Patient input summary sent for review to patient input groups||-|
|Patient group comments on input summary closed||-|
|Submission received||October 22, 2019|
|Submission accepted for review||November 05, 2019|
|Review initiated||November 06, 2019|
|Draft CADTH review report(s) sent to sponsor||January 27, 2020|
|Comments from sponsor on draft CADTH review report(s) received||February 05, 2020|
|CADTH review team's comments on draft CADTH review report(s) sent to sponsor||March 06, 2020|
|Canadian Drug Expert Committee (CDEC) meeting||March 18, 2020|
|CDEC recommendation sent to sponsor and drug plans||March 30, 2020|
April 01, 2020